Form 8-K · Current Report · Filed 2024-04-04
Boston Scientific's Merger with Axonics Receives Second Request from FTC
On April 3, 2024, Boston Scientific Corporation and Axonics, Inc.
- Filer
- Boston Scientific Corporation BSX · NYSE
- Filed
- Accession
- 0000885725-24-000037
- CIK
- 0000885725
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
each received a Second Request from the U.S. Federal Trade Commission (FTC) regarding their proposed merger. This request for additional information extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act until 30 days after both companies have substantially complied with the request. Boston Scientific and Axonics anticipate responding promptly and continuing to cooperate with the FTC in its review. The merger is expected to be completed in the second half of 2024, subject to the expiration or termination of the waiting period and the satisfaction of other customary closing conditions.
Items reported
Other Events
Market reaction
Close before filing
$68.13
Next session
+0.6%
Since filing
-31.4%
Latest close
$46.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BSX reporting the same item, with the next session's move:
About Boston Scientific Corporation
Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.
Never miss another BSX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.